Dominique L Ouellet
Overview
Explore the profile of Dominique L Ouellet including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
802
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Arizala J, Chomchan P, Li H, Moore R, Ge H, Ouellet D, et al.
J Vis Exp
. 2019 Jul;
(148).
PMID: 31305524
The HIV-1 infectious cycle requires viral protein interactions with host factors to facilitate viral replication, packaging, and release. The infectious cycle further requires the formation of viral/host protein complexes with...
2.
Cherif K, Gerard C, Rousseau J, Ouellet D, Chapdelaine P, Tremblay J
Mol Ther Nucleic Acids
. 2018 Sep;
12:19-32.
PMID: 30195758
Frataxin gene (FXN) expression is reduced in Friedreich's ataxia patients due to an increase in the number of GAA trinucleotides in intron 1. The frataxin protein, encoded by that gene,...
3.
Duchene B, Cherif K, Iyombe-Engembe J, Guyon A, Rousseau J, Ouellet D, et al.
Mol Ther
. 2018 Sep;
26(11):2604-2616.
PMID: 30195724
Duchenne muscular dystrophy (DMD), a severe hereditary disease affecting 1 in 3,500 boys, mainly results from the deletion of exon(s), leading to a reading frameshift of the DMD gene that...
4.
Arizala J, Takahashi M, Burnett J, Ouellet D, Li H, Rossi J
AIDS Res Hum Retroviruses
. 2018 May;
34(11):961-981.
PMID: 29804468
Combination antiretroviral therapy fails in complete suppression of HIV-1 due to drug resistance and persistent latency. Novel therapeutic intervention requires knowledge of intracellular pathways responsible for viral replication, specifically those...
5.
Duchene B, Iyombe-Engembe J, Rousseau J, Tremblay J, Ouellet D
Methods Mol Biol
. 2017 Oct;
1687:267-283.
PMID: 29067670
The discovery of the CRISPR-Cas9 system raises hope for the treatment of many genetic disorders. We describe here an approach based on the use of a pair of single guide...
6.
Tremblay J, Iyombe-Engembe J, Duchene B, Ouellet D
Mol Ther
. 2016 Dec;
24(11):1888-1889.
PMID: 27916992
No abstract available.
7.
Iyombe-Engembe J, Ouellet D, Barbeau X, Rousseau J, Chapdelaine P, Lague P, et al.
Mol Ther Nucleic Acids
. 2016 Jan;
5:e283.
PMID: 26812655
The CRISPR/Cas9 system is a great revolution in biology. This technology allows the modification of genes in vitro and in vivo in a wide variety of living organisms. In most...
8.
Ouellet D, Vigneault-Edwards J, Letourneau K, Gobeil L, Plante I, Burnett J, et al.
Retrovirology
. 2013 Aug;
10:86.
PMID: 23938024
Background: The transactivating response (TAR) element of human immunodeficiency virus type 1 (HIV-1) is the source of two functional microRNAs (miRNAs), miR-TAR-5p and miR-TAR-3p. The objective of this study was...
9.
Chung J, Zhang J, Li H, Ouellet D, DiGiusto D, Rossi J
Hum Gene Ther
. 2012 Jul;
23(11):1200-8.
PMID: 22834872
Combinational therapy with small RNA inhibitory agents against multiple viral targets allows efficient inhibition of viral production by controlling gene expression at critical time points. Here we explore combinations of...
10.
Lares M, Rossi J, Ouellet D
Trends Biotechnol
. 2010 Sep;
28(11):570-9.
PMID: 20833440
Small interfering RNAs (siRNAs) have been shown to effectively downregulate gene expression in human cells, giving them potential to eradicate disease. Prospects for clinical applications are discussed in this review,...